CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: A randomised trial (GABG trial IV-A-93)
Authors:
- Gunter von MinckwitzGMGunter von Minckwitz
- Erika GrafEGErika Graf
- Matthias GeberthMGMatthias Geberth
- Wolfgang EiermannWEWolfgang Eiermann
- Walter JonatWJWalter Jonat
- Bettina ConradBCBettina Conrad
- Klaus BrunnertKBKlaus Brunnert
- Bernd GerberBGBernd Gerber
- Sabine VesciaSVSabine Vescia
- Jörg WollertJWJörg Wollert
- Manfred KaufmannMKManfred Kaufmann
- 1 August 2006
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 42 (12) , 1780-1788
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Tamoxifen Versus Control After Adjuvant, Risk-Adapted Chemotherapy in Postmenopausal, Receptor-Negative Patients With Breast Cancer: A Randomized Trial (GABG-IV D-93)—The German Adjuvant Breast Cancer GroupJournal of Clinical Oncology, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Adjuvant Chemotherapy Followed by Goserelin Versus Either Modality Alone for Premenopausal Lymph Node-Negative Breast Cancer: A Randomized TrialJNCI: Journal of the National Cancer Institute, 2003
- Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast CancerJournal of Clinical Oncology, 2003
- Survival analyses from the ZEBRA studyEuropean Journal of Cancer, 2003
- Randomized Adjuvant Trial of Tamoxifen and Goserelin Versus Cyclophosphamide, Methotrexate, and Fluorouracil: Evidence for the Superiority of Treatment With Endocrine Blockade in Premenopausal Patients With Hormone-Responsive Breast Cancer—Austrian Breast and Colorectal Cancer Study Group Trial 5Journal of Clinical Oncology, 2002
- Goserelin Versus Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy in Premenopausal Patients With Node-Positive Breast Cancer: The Zoladex Early Breast Cancer Research Association StudyJournal of Clinical Oncology, 2002
- Ovarian ablation as adjuvant therapy for breast cancerSeminars in Oncology, 2001
- A note on quantifying follow-up in studies of failure timeControlled Clinical Trials, 1996
- “Classical” CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancerEuropean Journal of Cancer and Clinical Oncology, 1991